Five stabilized 111in-labeled neurotensin analogs in nude mice bearing HT29 tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 3, 2007, Pages 374-381

  Janssen, Paul J J M ^a   De Visser, Moniaue ^a   Verwijnen, Suzanne M ^a   Bernard, Bert F ^a   Srinivasan, Ananth ^b,c   Erion, Jack L ^b,d   Breeman, Wouter A P ^a   Vulto, Arnold G ^a   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Tyco Healthcare   (United States)

^c Berlex Laboratories   (United States)

^d BioSynthema Inc   (United States)

Author keywords

111In labeled neurotensin analogs; Biodistribution; Exocrine pancreatic cancer; HT29 tumors; Serum stability

Indexed keywords

ARGININE; INDIUM 111; LYSINE; NEUROTENSIN; NEUROTENSIN RECEPTOR; PENTETATE INDIUM IN 111; PENTETREOTIDE; DRUG DERIVATIVE; INDIUM; OLIGOPEPTIDE; PENTETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CELL STRAIN HT29; COLON; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; FEMUR; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; NUDE MOUSE; PANCREAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RECEPTOR AFFINITY; RENAL PROTECTION; SPLEEN; ANALYSIS OF VARIANCE; ANIMAL; CHEMISTRY; COLON TUMOR; DRUG EFFECT; HUMAN; KIDNEY; RADIOGRAPHY; TISSUE DISTRIBUTION; XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; COLONIC NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; KIDNEY; LYSINE; MALE; MICE; MICE, NUDE; NEUROTENSIN; OLIGOPEPTIDES; PENTETIC ACID; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34447503736     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.369.a     Document Type: Article

References (32)

1. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. In: Freeman L. Nuclear Medicine Annual. New York: Raven Press, 1995:1.
2. Williamson RC. Pancreatic cancer: The greatest oncological challenge. Br Med J (Clin Res Ed) 1988;296: 445.
3. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998;7:67.
4. Gutniak M, Rosenqvist U, Grimelius L, et al. Report on a patient with watery diarrhoea syndrome caused by a pancreatic tumour containing neurotensin, enkephalin, and calcitonin. Acta Med Scand 1980;208:95.
5. Ehlers RA, Kim S, Zhang Y, et al. Gut peptide receptor expression in human pancreatic cancers. Ann Surg 2000;231:838.
6. Reubi JC, Waser B, Friess H, et al. Neurotensin receptors: A new marker for human ductal pancreatic adenocarcinoma. Gut 1998;42:546.
7. Reubi JC, Waser B, Schaer JC, et al. Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas. Int J Cancer 1999;82:213.
8. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 2003; 44:1649.
9. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302.
10. Ishizuka J, Townsend CM, Jr, Thompson JC. Neurotensin regulates growth of human pancreatic cancer. Ann Surg 1993;217:439.
11. Wang L, Friess H, Zhu Z, et al. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 2000;6:566.
12. Kitabgi P, De Nadai F, Rovere C, et al. Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. Ann N Y Acad Sci 1992;668:30.
13. 99mTc-labeled neurotensin peptide 8-13. Nucl Med Biol 2006;33:505.
14. 99mTc. J Med Chem 2006; 49:4767.
15. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem 2006;49:1833.
16. Garcia-Garayoa E, Maes V, Blauenstein P, et al. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl Med Biol 2006;33:495.
17. Garcia-Garayoa E, Allemann-Tannahill L, Blauenstein P, et al. In vitro and in vivo evaluation of new radiolabeled neurotensin(8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 2001;28:75.
18. Lugrin D, Vecchini F, Doulut S, et al. Reduced peptide bond pseudopeptide analogues of neurotensin: Binding and biological activities, and in vitro metabolic stability. Eur J Pharmacol 1991;205:191.
19. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imag 2003;30: 1134.
20. 177Lu at high specific activities. Eur J Nucl Med Mol Imag 2003;30:917.
21. Liu S, Edwards DS. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001;12:7.
22. Breeman WA, Kwekkeboom DJ, De Blois E, et al. Radiolabeled regulatory peptides for imaging and therapy. Anti-Cancer Agents Medic Chem 2007;7:345.
23. +. Nucl Med Biol 2004; 31:821.
24. Rettenbacher M, Reubi JC. Localization and characterization of neuropeptide receptors in human colon. Naunyn Schmiedebergs Arch Pharmacol 2001;364:291.
25. Garcia-Garayoa E, Blauenstein P, Bruehlmeier M, et al. Preclinical evaluation of a new, stabilized neurotensin (8-13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med 2002;43:374.
26. Bernard BF, Krenning EP, Breeman WA, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929.
27. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388.
28. 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res 1996; 56:3788.
29. Lang L, Jagoda E, Wu C, et al. Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: The pharmacokinetics of two PET-labeled low-molecular-weight proteins. Q J Nucl Med 1997;41:53.
30. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109.
31. Bergmann R, Scheunemann M, Heichert C, et al. Biodistribution and catabolism of (18)F-labeled neurotensin (8-13) analogs. Nucl Med Biol 2002;29:61.
32. Bruehlmeier M, Garayoa EG, Blanc A, et al. Stabilization of neurotensin analogues: Effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol 2002;29:321.